Gliomas are the commonest primary tumours of the brain and glioblastoma multiforme (GBM) represents more than 50% of this group. GBM remains a neurosurgical conundrum since patients often succumb to the disease within one year. Surgery followed by radiation and medical regimens over the years have had minimal impact on the prognosis of patients with this cancer and hence, alternative and novel therapeutic modalities are required if the survival of patients with this disease is to be significantly improved. The ATM gene, which is mutated in the disease ataxia-telangiectasia (A-T), is implicated in response to radiation-induced DNA damage, leading to profound radiosensitivity. By reducing the levels of ATM in the radioresistant GBM cells through antisense or RNA interference (RNAi) technology delivered by lentiviruses, malignant GBM tumour cells were successfully sensitised to radiation treatment. In conjunction with surgery, this strategy will provide an enhanced therapeutic intervention especially in the case of GBM where the tumour is untreatable. In this thesis, analysis of the D-3-Phosphoglycerate dehydrogenase promoter in a GBM cell line as well as the development of a novel rat model for GBM using a bioluminescent F98 cell line will also be presented.